Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
Public ClinicalTrials.gov record NCT04338061. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
Study identification
- NCT ID
- NCT04338061
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Enrollment
- 1,166 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2020 (Actual)
- Primary completion
- Oct 2, 2023 (Actual)
- Completion
- Mar 19, 2024 (Actual)
- Last update posted
- Mar 21, 2025
2020 – 2024
United States locations
- U.S. sites
- 38
- U.S. states
- 19
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 752 | Cullman | Alabama | 35058 | — |
| Research Site 741 | Scottsdale | Arizona | 85258 | — |
| Research Site 704 | Tucson | Arizona | 85710 | — |
| Research Site 751 | Hanford | California | 93230 | — |
| Research Site 737 | West Hollywood | California | 90048 | — |
| Research Site 759 | Colorado Springs | Colorado | 80907 | — |
| Research Site 725 | Fort Collins | Colorado | 80528 | — |
| Research Site 746 | Altamonte Springs | Florida | 32714 | — |
| Research Site 718 | Jacksonville | Florida | 32209 | — |
| Research Site 702 | Naples | Florida | 34105 | — |
| Research Site 740 | Orlando | Florida | 32806 | — |
| Research Site 726 | Port Charlotte | Florida | 33952 | — |
| Research Site 719 | Sarasota | Florida | 34243 | — |
| Research Site 743 | Tampa | Florida | 33612 | — |
| Research Site 707 | Tampa | Florida | 33634 | — |
| Research Site 732 | Vero Beach | Florida | 32960 | — |
| Research Site 705 | Weeki Wachee | Florida | 34607 | — |
| Research Site 753 | West Palm Beach | Florida | 33407 | — |
| Research Site 742 | Honolulu | Hawaii | 96817 | — |
| Research Site 715 | Evanston | Illinois | 60201 | — |
| Research Site 714 | Fort Wayne | Indiana | 46804 | — |
| Research Site 744 | Lafayette | Indiana | 47904 | — |
| Research Site 717 | Overland Park | Kansas | 66212 | — |
| Research Site 735 | Nicholasville | Kentucky | 40356 | — |
| Research Site 706 | Scarborough | Maine | 04074 | — |
| Research Site 738 | Detroit | Michigan | 48202 | — |
| Research Site 723 | St Louis | Missouri | 63128 | — |
| Research Site 724 | Amherst | New York | 14226 | — |
| Research Site 736 | Asheville | North Carolina | 28006 | — |
| Research Site 712 | Chapel Hill | North Carolina | 27599 | — |
| Research Site 730 | Raleigh | North Carolina | 27607 | — |
| Research Site 728 | Winston-Salem | North Carolina | 27157 | — |
| Research Site 711 | Canton | Ohio | 44735 | — |
| Research Site 757 | Columbus | Ohio | 43214 | — |
| Research Site 734 | Dayton | Ohio | 45459 | — |
| Research Site 748 | Philadelphia | Pennsylvania | 19107 | — |
| Research Site 703 | San Antonio | Texas | 78258 | — |
| Research Site 721 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 240 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04338061, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04338061 live on ClinicalTrials.gov.